JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS
AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
A&A International Anesthesia Research Society
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huettemann, E.
Right arrow Articles by Nuttall, G. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huettemann, E.
Right arrow Articles by Nuttall, G. A.
Anesth Analg 2000;91:1561
© 2000 International Anesthesia Research Society

LETTERS TO THE EDITOR

Hetastarch and Hydroxyethyl Starch Are Not the Same

Egbert Huettemann, MD, DEAA

Klinik für Anästhesiologie und Intensivtherapie Friedrich-Schiller-Universität Jena D-07740 Jena, Germany

To the Editor:

Knutson et al. (1) did not describe the hetastarch preparation used adequately. The average molecular weight, distribution of molecular weight, and the degree and pattern (C2/C6 ratio) of the substitution of hydroxyethyl starch (HES) can influence hemostasis. Treib et al. (2) investigated the effect of different HES preparations in patients suffering from vasospasm after subarachnoid hemorrhage during a 10-day intravascular volume therapy. When using a HES with an average molecular weight of 200.000, the substitution of 0.5 and a C2/C6 ratio of 6 did not lead to significant reductions in factor VIII:C or von-Willebrand-Ristocetin-Cofactor; yet, a preparation with the same average molecular weight, a degree of substitution of 0.62, and an higher C2/C6 ratio (10) caused profound reductions. In Europe, a large variety of HES solutions are available (70.000/0.5; 130.000/0.4; 200.000/0.5 [with different C2/C6 ratios ranging from 6 to 13]; 200.000/0.62; 450.000), dominated by the medium molecular weight, easily degradable HES (200.000/0.5). Thus, European colleagues may find it hard to decide whether their current practice is to be challenged by the data provided by Knutson et al. (1).

References

  1. Knutson JE, Deering JA, Hall FW, et al. Does intraoperative hetastarch administration increase blood loss and transfusion requirements after cardiac surgery? Anesth Analg 2000; 90: 801–7.[Abstract/Free Full Text]
  2. Treib J, Baron JF, Grauer-MT, Strauss-RG. An international view of hydroxyethyl starches. Intensive Care Med 1999;25:258–68.
  3. Treib J, Haass A, Pindur G, et al. Influence of the C2/C6 hydroxyethylation ratio of hydroxyethyl starch (HES) on hemorheology, coagulation and elimination kinetics. Thromb Haemost 1995; 74: 1452–6.[ISI][Medline]
 

Response

Gregory A. Nuttall, MD

Department of Anesthesiology Mayo Clinic Rochester, MN 55901

In Response:

I would like to thank Dr. Huettemann for his thoughtful letter to the editor. As noted by Treib et al. (1), there is only one type of hydroxyethyl starch available in the United States, whereas several hydroxyethyl starch preparations are widely used in Europe. The results of our study should only be applied to the preparation used in the United States (Hespan®, Abbott Laboratories, North Chicago, IL; average molecular weight 450,000 daltons, substitution of 0.7) or similar European preparations, because they induce a greater degree of anticoagulation than the smaller, more easily degraded hydroxyethyl starch preparations (1). Furthermore, as the anticoagulant effects of hydroxyethyl starch may potentiate the known coagulopathic state induced by cardiopulmonary bypass and exacerbate bleeding, the results of our study can only be applied to patients undergoing cardiopulmonary bypass.

References

  1. Treib J, Baron JF, Grauer MT, Strauss RG. An international view of hydroxyethyl starches. Intensive Care Med 1999; 25: 258–68.[ISI][Medline]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huettemann, E.
Right arrow Articles by Nuttall, G. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huettemann, E.
Right arrow Articles by Nuttall, G. A.

Lippincott, Williams & Wilkins Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins with the assistance of Stanford University Libraries' HighWire Press®. Copyright 2006 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999 HighWire Press